CYCN - Company ID 0001755237
The table below shows Cyclerion Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $875.00K | $93.00K | $81.00K | $194.00K | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $730.00K | $348.00K | $56.00K | $36.00K | $81.00K | $105.00K |
Cyclerion Therapeutics, Inc. reported annual revenue of $2.07M for fiscal year 2025. That is up 3.7% from $2.00M in fiscal 2024. Over the 7 fiscal years shown, annual revenue declined from $4.51M (FY 2019) to $2.07M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.48M |
| $1.53M |
| $1.71M |
| $1.50M |
| $1.24M |
| $1.28M |
| Operating income | -$3.21M | -$1.01M | -$1.67M | -$1.46M | -$1.13M | -$1.38M |
| Income tax | - | - | - | - | - | - |
| Net income | -$3.18M | -$976.00K | -$324.00K | -$1.43M | -$723.00K | -$1.32M |
| EPS (diluted) | -$0.76 | -$0.30 | -$0.11 | -$0.56 | -$0.29 | -$0.53 |